Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Two proprietary compounds of Allon Therapeutics, one of which is an Alzheimer's disease treatment candidate, have the potential to become new treatments for eye diseases, including glaucoma, according to results from a preclinical study.
Subscribe to our email newsletter
The two compounds are AL-108, Allon’s lead product candidate currently being evaluated in human clinical trials as a treatment for Alzheimer’s disease, and AL-209, one of Allon’s preclinical-stage product candidates.
Several diseases of the optic nerve and retina, including glaucoma, involve the degeneration of retinal ganglion cells, a group of specialized neurons of the visual system responsible for transmitting information to the brain.
The study demonstrated that administration of Allon’s proprietary drugs AL-108 and AL-209 enhanced the survival of retinal ganglion cells by 167% and 177% respectively, compared with the control, and enhanced neurite growth by 117% and 126% respectively, compared with the control.
Gordon McCauley, president of Allon, said the study indicates the potential of AL-108 and AL-209 as new treatments for diseases of the optic nerve and retina.
“This early-stage study adds to our extensive body of research that confirms the potential of AL-108 and our other compounds to protect against and treat a number of neuro-degenerative diseases and conditions,” said McCauley. “Accordingly, we are evaluating AL-108 in human clinical trials for Alzheimer’s disease and will expand our clinical development program in the coming months.”